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Effect of dietary protein restriction on nutritional status in the Modi-
fication of Diet in Renal Disease Study. The safety of dietary protein and
phosphorous restriction was evaluated in the Modification of Diet in
Renal Disease (MDRD) Study. In Study A, 585 patients with a glomerular
filtration rate (GFR) of 25 toSS ml/min/l.73 m2 were randomly assigned to
a usual-protein diet (1.3 glkglday) or a low-protein diet (0.58 g/kglday). In
Study B, 255 patients with a GFR of 13 to 24 ml/min/l.73 m2 were
randomly assigned to the low-protein diet or a very-low-protein diet (0.28
g/kg/day), supplemented with a ketoacid-amino acid mixture (0.28 g/kg/
day). The low-protein and very-low-protein diets were also low in phos-
phorus. Mean duration of follow-up was 2.2 years in both studies. Protein
and energy intakes were lower in the low-protein and very-low-protein diet
groups than in the usual-protein group. Two patients in Study B reached
a "stop point" for malnutrition. There was no difference between random-
ized groups in the rates of death, first hospitalizations, or other "stop
points" in either study. Mean values for various indices of nutritional
status remained within the normal range during follow-up in each diet
group. However, there were small but significant changes from baseline in
some nutritional indices, and differences between the randomized groups
in some of these changes. In the low-protein and very-low-protein diet
groups, serum albumin rose, while serum transferrin, body wt, percent
body fat, arm muscle area and urine creatinine excretion declined.
Combining patients in both diet groups in each study, a lower achieved
protein intake (from food and supplement) was not correlated with a
higher rate of death, hospitalization or stop points, or with a progressive
decline in any of the indices of nutritional status after controlling for
baseline nutritional status and follow-up energy intake. These analyses
suggest that the low-protein and very-low-protein diets used in the MDRD
Study are safe for periods of two to three years. Nonetheless, both protein
and energy intake declined and there were small but significant declines in
various indices of nutritional status. These declines are of concern because
of the adverse effect of protein calorie malnutrition in patients with
end-stage renal disease. Physicians who prescribe low-protein diets must
carefully monitor patients' protein and energy intake and nutritional
status.
Dietary protein restriction has long been advocated to amelio-
rate the symptoms of renal failure and to slow the progression of
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chronic renal disease. However, the safety of low-protein diets
and their long-term effects on nutritional status have not been
adequately evaluated. This evaluation is especially important
because of the well-recognized adverse effects of malnutrition in
patients beginning dialysis for end-stage renal disease.
The Modification of Diet in Renal Disease (MDRD) Study was
the largest clinical trial to examine whether the prescription of low
protein and low phosphorus diets would retard the rate of
progression of renal disease and whether such therapy was safe
for long term use [1]. During the course of the study, patients with
moderate to advanced renal disease from various causes were
randomly assigned and trained to follow specific diets, and their
renal function, dietary intake and nutritional status were moni-
tored periodically. The primary and secondary analyses of the
efficacy of dietary protein restriction have been reported else-
where [1—3], as have two meta-analyses [4, 5]. Although not
definitive, these analyses provide some support for the hypothesis
that protein restriction slows the progression of renal disease.
This manuscript examines the effects of both prescribed and
achieved protein intake on nutritional status during the course of
the MDRD Study. Specifically, we compared the randomized
groups for various outcomes related to nutritional status. In
addition, we correlated the achieved dietary protein intake with
these parameters. These results demonstrate the safety of dietary
protein restriction over two to three years in patients with
moderate to advanced renal disease.
METHODS
The MDRD Study was a multicenter, randomized clinical trial
of the effects of restriction of dietary protein and phosphorus and
strict blood pressure control on the progression of chronic renal
disease of various causes. The design, recruitment and baseline
characteristics of the patients, effects of the diet and blood
pressure interventions, and dietary adherence have been de-
scribed previously [1, 6—121.
Study design
The study was approved by the review boards at all participating
institutions, and informed consent was obtained from all patients.
Baseline period. Patients were eligible to enter the baseline
period if they were 18 to 70 years of age, had chronic renal disease
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with a serum creatinine of 1.4 to 7.0 mg/dl (men) or 1.2 to 7.0
mg/dl (women). Patients with diabetes mellitus requiring insulin
or a previous renal transplant were excluded. A total of 2507
patients were screened, and 1785 individuals entered the baseline
period for assessment of glomerular filtration rate (GFR), dietary
intake, nutritional status and blood pressure. Patients with a
GFR  25 ml/min/1.73 m2 were assigned a dietary protein
intake > 1.0 g/kg/day. Patients with a GFR  24 mI/mm/I .73 m2
were assigned a dietary protein intake  0.6 g/kg/day. All patients
were required to satisfy the following criteria regarding their
nutritional status in order to be eligible for randomization:
relative body wt 80% to 160%, defined as body wt/standard body
wt X 100%, as determined from the National Health and Nutrition
Evaluation Survey (NHANES) I and II data [13]; serum albumin
of 3.0 gIdl or greater; and urine protein less than 10 g/day. After
three months, GFR, protein intake and blood pressure were
re-assessed. A total of 585 patients with a GFR of 25 to 55
ml/min/1.73 m2 and protein intake  0.9 g/kg/day entered Study
A, and 255 patients with a GFR of 13 to 24 mI/min/l.73 m2 entered
Study B.
Follow-up period. Patients in Study A were randomly assigned
to a usual (1.3 g/kg/day) or a low protein diet (0.58 g/kg/day).
Patients in Study B were randomly assigned to the same low
protein diet as in Study A or a very low protein diet (0.28 g/kg/day)
supplemented with a mixture of ketoacids and amino acids (0.28
glkg/day). The mean duration of the follow-up period was 2.2
years (range, 0 to 44 months). The nutrition intervention program,
"Protein Wise," was designed by the clinical center dietitians with
the Nutrition Coordinating Center (NCC) at the University of
Pittsburgh and has been described in detail previously [14]. The
program was based primarily on behavioral principles and tech-
niques and was similar across all diet groups, although the content
was tailored to support the specific goals of each diet group. The
major goal was to support long-term adherence by developing
self-management skills (the ability to select foods and prepare
meals which meet study goals) and increase feelings of self-
efficacy. The NCC trained the dietitians, developed the interven-
tion materials and Manual of Operations (available upon request
from the NCC), coordinated daily phone contact to individual
clinical center dietitians and conference calls which focussed on
identifying and solving adherence problems for individual pa-
tients. The NCC also supplied the clinical centers with a wide
variety of special food products, including low-protein foods and
high-calorie, low-protein supplements. Protein intake was as-
sessed monthly from urine urea nitrogen (UUN) excretion.
Nutritional status was assessed from measurements of serum
levels of albumin and transferrin, body weight, percent body fat
(computed from the thickness of biceps, triceps and subscapular
skinfolds), arm muscle area, and urine creatinine. Safety of the
diet interventions was assessed by examining the frequency of
action items and stop points, hospitalizations and deaths. Details
of the dietary intervention, methods for follow-up measurements,
and definitions of action items and stop points are reported in the
Appendix and elsewhere [13—22].
Statistical methods
Hypothesis tests were regarded as statistically significant if P
0.05 (two sided). No adjustment was made for multiple compar-
isons.
Comparisons of randomized groups. Within each diet group in
Study A and Study B during the baseline and follow-up periods,
the values for nutritional intake, anthropometry and biochemical
indices of nutritional status, with few exceptions, were not differ-
ent between patients randomized to the usual and low blood
pressure goals. Consequently, comparisons of the diet groups are
presented for all patients regardless of blood pressure assignment.
Because normal values for nutritional status variables differ
between men and women [6], results are shown for each gender.
Changes in nutritional status parameters during follow-up were
expressed as the change from the final baseline measurement (B2
or B3). To account for different lengths of follow-up, plots of the
pattern of change are based on a statistical model in which the
estimated mean change to later follow-up times takes into account
early measurements from patients with shorter follow-up [23]. As
shown in these plots, some variables changed gradually after
randomization, but others changed abruptly within the first four
months and gradually thereafter. Therefore, we computed the
mean follow-up value for each nutritional status variable in an
individual as the mean of all values from the fourth month (F4)
until the end of the follow-up period. Similarly, we defined mean
follow-up protein intake in an individual as the average of all
measurements of protein intake beginning with the F4 visit. In
Study A, the median number of monthly UUN measurements
used in calculating mean follow-up protein intake was 21, with at
least six measurements available for 552 of 585 (94%) patients. In
Study B, the median number was 20, with at least six measure-
ments available for 230 of 255 (90%) patients. Baseline and
follow-up characteristics and changes during follow-up were com-
pared between the diet groups using t-tests, analysis of variance,
or chi-square tests, as appropriate. The effect of the diet inter-
ventions on urine creatinine was also analyzed using a two-slope
model with a breakpoint at F4, in which the decline in urine
creatinine in each patient was assumed to have one slope from B3
to F4 and possibly a different slope from F4 to the end of
follow-up [1].
Correlation of safety measures and nutritional status with protein
intake. For correlational analyses, we combined patients in both
diet groups in each study (Study A and Study B) and related safety
measures and nutritional status to achieved mean follow-up
protein intake estimated from UUN. To maximize the number of
patients included in these analyses, mean follow-up protein intake
for an individual was computed beginning with the second fol-
low-up visit (F2).
For descriptive purposes, measures of safety (rates of death,
hospitalization and reaching a stop point) are presented for
subgroups of patients defined by quartiles of mean follow-up
protein intake. Only the first hospitalization was used in the
analyses to avoid giving too much weight to patients with multiple
hospitalizations. For statistical tests, time-dependent Cox regres-
sion analyses [24] were used to relate each safety measure to the
mean follow-up protein intake (only including measurements
prior to the occurrence of the outcomes).
The average rates of change in nutritional status variables
beginning with the F4 visit were estimated for each patient by
regressing the nutritional status measurements beginning with F4
against time. Regression coefficients and Pearson correlation
coefficients were computed for the relationships between the rates
of changes in these variables and mean follow-up protein intake.
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Table 1. Characteristics at the end of baseline for the randomized
patients by study and diet group
Study A Study B
Usual Low Low Veiy low
protein protein protein protein
diet diet diet diet
Number of 186/108 171/120 78/5t 73/53
men/women
Age years 52.5 12.2 51.8 t2.1 51.1 12.8 50.5 12.9
GFR ml/min/1.73 m2 37.9 8.78 39.3 8.97 18.7 3.21 18.3 3.55
Urine urea nitrogen 10.8 2.46 10.5 2.67 7.52 2.17 7.63 2.41
g/day
Serum urea nitrogen 32.3 9.34 31.3 10.3 46.0 12.7 46.3 12.5
mg/dl
Serum creatinine 1.98 0.52 1.89 0.52 3.46 0.85 3.39 0.91
mg/dl
Hematocrit % 40.1 4.85 39.5 4.59 35.8 5.06 36.1 5.14
Data are given as mean standard deviation. Study A, GFR 25 to 55
ml/min/1.73 m2; Study B, GFR 13 to 24 ml/min/173 m2.
These analyses included only patients with  one year of fol-
low-up (553 patients in Study A and 219 patients in Study B).
Because these were correlational analyses and were not based on
a direct comparison of randomly assigned groups, these analyses
were repeated after controlling for possible confounding variables
related to nutritional status. Covariates in the analysis included
mean follow-up energy intake and the following baseline vari-
ables: age, gender, body wt, desire to lose weight, percent body fat,
serum concentrations of albumin, transferrin and total choles-
terol, and urine creatinine excretion per kg body wt. For these
analyses, the Pearson partial correlation coefficient is reported.
RESULTS
Comparisons of randomized groups
Baseline characteristics. The most common causes of renal
disease were polycystic kidney disease (25% of all patients) and
glomerular diseases (24%). Patients' gender, age, and selected
measures of renal function are shown in Table 1. By definition,
patients in Study B had more advanced renal disease than in Study
A, but within each study, the forgoing characteristics were similar
between diet groups.
Mean baseline protein and energy intakes and biochemical and
anthropometric parameters are shown in Table 2. The nutrient
intake calculated from the dietary diaries and interviews and from
urine urea excretion arc reported in more detail elsewhere [11,
121. In comparison with patients in Study A, both men and women
in Study B had significantly lower mean values for the following
parameters: protein and energy intake, serum transferrin, body
wt, percent body fat, arm muscle area and urine creatinine
excretion. Mean serum albumin concentrations did not differ
between Studies A and B. Within each study, however, there were
few differences between the two diet groups for either men or
women. In Study A men, body wt was slightly lower in the
low-protein diet group as compared to the usual-protein diet
group. In Study B women, arm muscle area was lower in the
very-low-protein diet group as compared to the low-protein diet
group.
Follow-up characteristics. Table 3 shows the mean follow-up
values of the nutritional status variables. As reported elsewhere
[1—3, ii], there were large significant differences in dietary protein
intake (from food only) between the usual and the low-protein
diet groups in Study A and between the low and the very-low-
protein diet groups in Study B. In addition, there was a small, but
significant difference in total protein intake (from food and amino
acids in the supplement) between the low-protein and the very-
low-protein diet groups in Study B. In all diet groups, men and
women had similar protein intake (and total protein intake) per
kg body wt during follow-up.
Also as reported elsewhere [11], there was a significant differ-
ence in energy intake during the follow-up between the usual and
low-protein diet groups in Study A, but not between the low-
protein and very-low-protein diet groups in Study B (Table 3). In
all diet groups, women had lower energy intake per kg body wt
than men in all diet groups.
Biochemical and anthropometric indices of nutritional status
during follow-up were generally well within normal limits in all
four diet groups. Thus, mean serum albumin and transferrin levels
were normal. Relative body wt averaged above 100% in each
group, and the arm muscle area and percent body fat were also
within normal ranges. However, many of these variables differed
significantly between the diet groups in both Study A and Study B.
The men in the low-protein diet group in Study A had lower mean
serum transferrin, body wt, relative body wt, percent body fat, arm
muscle area and urine creatinine excretion compared to men in
the usual-protein diet group. Similarly, women in the low-protein
diet group in Study A had lower serum transferrin and urine
creatinine excretion compared to women in the usual-protein diet
group. Both men and women in the very-low-protein diet group in
Study B had lower urine creatinine excretion than patients in the
low-protein diet group.
Changes from baseline to follow-up. Figures 1 to 6 show changes
in biochemical and anthropometric indices of nutritional status
during baseline and follow-up. The data for men and women in
each diet group are combined in these Figures because the
direction of the changes did not differ by gender.
In Study A, these variables did not change significantly from
baseline to follow-up in the usual-protein diet group. However, in
the low-protein diet group, serum albumin rose significantly, while
serum transferrin, body wt, relative body wt, arm muscle area and
urine creatinine excretion declined significantly. The decline in
serum transferrin, body wt, arm muscle area and urine creatinine
was significantly greater in the low-protein diet group compared
with the usual-protein diet group.
In Study B, the low-protein diet group had a significant rise in
serum albumin, hut significant declines in serum transferrin, body
wt, percent body fat, arm muscle area and urine creatinine
excretion. Similar findings were observed in patients in the
very-low-protein diet group, except for percent body fat. The only
significant differences between the diet groups were that percent
body fat declined more in the low-protein diet group and urine
creatinine excretion declined more in the very-low-protein diet
group.
Importantly, with the exception of the decrease in urine creat-
mine excretion, the above described changes in nutritional status
from baseline to follow-up were usually of minor absolute mag-
nitude. The temporal pattern of changes in these variables is also
of interest. The decline in serum transferrin and weight in the
low-protein and very-low-protein diet groups occurred abruptly
after randomization and appeared to stabilize after about the
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Table 2. Parameters of nutritional status at the end of baseline by gender, study and diet groupa
fourth month of follow-up. Changes in other parameters occurred
more gradually.
Urine creatinine excretion declined approximately 15% to 20%
from baseline. Inspection of Figure 6 reveals an abrupt decline in
some diet groups during the first four months (B3 to F4), and a
gradual decline thereafter in all four diet groups. Therefore, we
performed additional analyses comparing the decline in urine
creatinine between randomized groups both during and after the
first four months. In Study A, the decline was significantly faster
in the low-protein diet group as compared to the usual-protein
diet group both during (P < 0.001) and after (P = 0.013) the first
four months of follow-up. In Study B, the decline in the very-low
protein diet group as compared to the low-protein diet group was
significantly faster during the first four months of follow-up (P <
0.001), but significantly slower thereafter (P < 0.001).
Safety measures. The rate of deaths, hospitalizations and stop
points during follow-up are shown in Table 4. In both studies, the
rates of such events were low, and there were no significant
differences between diet groups in either study.
Only deaths that occurred prior to reaching a stop point are
shown in Table 4. In Study A, there were two deaths in the
low-protein diet group, both due to cardiovascular disease, com-
pared to nine deaths in the usual-protein diet group, five due to
cardiovascular disease, two to cancer, one to respiratory disease,
and one to trauma. Four other patients died after reaching a stop
point, three patients in the low-protein diet group (cardiovascular
disease in two patients and cancer in one patient) and one patient
in the usual-protein diet group (renal failure). After extensive
review, the External Monitoring Committee concluded that nei-
ther the higher number of deaths in the usual protein diet group,
nor the causes of death, was related to the Study diets.
In Study B, there were four deaths in the very-low-protein diet
group and two deaths in the low-protein diet group. Causes of
death in the very-low-protein diet group were cardiovascular
disease in two patients and trauma in two patients, and cardio-
vascular disease in both patients in the low-protein diet group. In
addition, 10 patients died after reaching a stop point. These
included six patients in the very-low-protein diet group (two
patients each with cardiovascular disease, cancer, or infection)
and four patients in the low-protein diet group (three patients
with cardiovascular disease and one patient with cerebrovascular
disease).
In Study A, 84 patients reached a stop point (14%), mostly due
to rapidly declining GFR (60 patients, 10%) or renal failure (12
patients, 2%). No patients in Study A reached a stop point due to
malnutrition. Twelve patients (2%) reached stop points due to
serious medical conditions. These included six patients in the
low-protein diet group (one patient who became pregnant, two
patients who developed a stroke, and one patient each who
developed acute renal failure, diabetes requiring insulin, or
cancer), and six patients in the usual-protein diet group (three
patients who developed diabetes requiring insulin and one patient
Study A
Usual Low Low Very low
protein diet
-
protein diet protein diet protein diet
Study B
Men
Number of subjects 163—186 143—171 69—78 71—73
Protein intake from UUN g/kg/day 1.12 0.18 1.12 0.19 0.84 0.20 0.87 0.18
Energy intake kcal/kg/day 27.6 7.01 27.6 7.27 25.3 7.04 25.9 7.48
Albumin gIdi 4.05 0.35 4.04 0.36 4.05 0.36 4.08 0.33
Transferrin mg/dl
Body weight kg
272 44.5
89.0 14.9
270 40.1
85.4 13.5"
257 40.4
80.8 11.5
266 48.3
81.9 11.16
Relative body weight % 113 14.9 110 13.5 104 11.7 106 12.5
Biceps skinfold mm 7.74 4.55 6.90 3.71 5.88 2.85 6.01 2.69
Triceps skinfold mm 14.9 6.39 13.7 6.05 13.1 5.97 12.8 5.09
Subscapular skinfold mm 20.7 7.08 19.4 6.65 17.1 5.63 16.5 5.04
Percent body fat % 28.3 5.87 27.0 6.51 25.9 5.46 25.3 5.20
Arm muscle area cm2 48.6 13.7 46.8 11.9 41.5 9.64 43.2 11.2
Urine creatinine mg/day 1743 325 1700 320 1421 318 1465 367
Women
Number of subjects 93—108 107—120 48—51 43—53
Protein intake from UUN g/kg/day 1.13 0.17 1.12 0.22 0.89 0.15 0.87 0.21
Energy intake kcal/kg/day 26.4 6.64 26.9 7.40 24.1 5.83 23.3 5.81
Albumin g/dl 4.01 0.33 3.97 0.32 3.86 0.36 3.91 0.37
Transferrin mg/dl 288 47.8 288 49.1 270 41.2 266 46.3
Body weight kg 71.8 15.0 70.5 14.3 67.6 12.4 66.1 15.7
Relative body weight % 114 18.2 113 17.1 109 15.8 108 22.1
Biceps skinfold mm 11.9 5.77 11.6 6.34 9.47 4.81 10.5 7.42
Triceps skinfold mm 23.0 7.01 22.5 7.05 20.4 6.67 19.4 7.56
Subscapular skinfold mm 19.7 7.61 19.5 7.57 18.2 7.89 16.1 8.00
Percent body fat % 35.8 5.64 35.0 5.94 33.2 6.53 32.0 6.84
Arm muscle area cm2 30.0 13.7 29.1 11.7 29.3 10.6 23.6 10.4c
Urine creatinine mg/day 1153 271 1120 218 1021 181 980 202
Data arc given as mean standard deviation. Study A, GFR 25 to 55 ml/min/1.73 m2; Study B, GFR 13 to 24 ml/min/173 m2
"P 0.05 between diet groups
P 0.01 between diet groups
each with cardiomyopathy, cancer, or severe liver disease). In
Study B, 103 patients (40%) reached stop points, including 94
patients (37%) due to renal failure. Two patients (0.8%, one from
each diet group) reached a stop point because of malnutrition
related to weight loss. Seven patients (2.7%) reached stop points
due to serious medical conditions. These included four patients in
the very-low-protein diet group (one patient who became preg-
nant and one patient each who developed diabetes requiring
insulin, severe arthritis, or cancer) and three patients in the
low-protein diet group (one each with cancer, emphysema, or
ischemic bowel disease).
A large number of patients reached action items requiring
dietary modification. In Study A, significantly more patients in the
low-protein diet group than in the usual-protein diet group
reached action items for weight loss (29% vs. 18%), declining
serum transferrin (9.3% vs. 4.1%) and low serum magnesium
(16% vs. 7.5%). Fewer patients in the low-protein diet than in the
usual-protein diet group reached action items for weight gain
(25% vs. 40%), high serum phosphorus (12% vs. 26%), high
serum potassium (10% vs. 17%), and low serum bicarbonate
(7.2% vs. 20%). There were no significant differences between the
number of patients in the low-protein and usual-protein diet
groups reaching action items for declining serum albumin (8% vs.
11%) or low serum albumin (3% vs. 3%). In Study B, fewer
patients in the very-low-protein diet group than in the low-protein
diet group had action items for high serum LDL cholesterol (31%
vs. 48%). There were no significant differences between the
very-low-protein and low-protein diet groups in the number of
patients reaching action items for weight loss (40% vs. 30%),
declining serum albumin (10% vs. 5%), low serum albumin (3%
vs. 2%) or declining serum transferrin (10% vs. 12%).
Correlations of safety measures and nutritional status with
achieved protein intake
For these analyses, patients in both diet groups were combined
in each study. Safety measures and nutritional status variables
were correlated with follow-up achieved protein intake in Study A
and with achieved total protein intake in Study B.
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Table 3. Parameters of nutritional Status during follow-up by gender, study and diet groupa
Study A
Usual Low Low Veiy low
protein diet protein diet protein diet protein diet
Study B
Men
Number of subjccts' 179—183 165—170 74—77 69—71
Protein intake from UUNg/kg/dayc 1.11 0.14 0.77 O.13 0.72 0.11 0.48 0.ll
Total protein intake from UUN 1.11 0.14 0.77 0.l3 0.72 0.11 0.66 o1l
g/kg/day2
Energy intake kcal/kg/day 26.7 5.44 23.1 5.72 22.5 4.83 22.7 4.92
Albumin g/dl 4.09 0.34 4.12 0.31 4.14 0.32 4.11 0.35
Transferrin mg/dl 271 42.3 258 35.0 250 36.6 258 44.1
Body weight kg 88.5 14.6 83.2 l2.8 79.6 11.5 79.3 10.9
Relative body weight % 112 14.4 107 12.9 102 11.9 103 11.2
Biceps skinfold mm 7.65 3.67 6.49 3.1 l 5.96 3.60 6.33 3.03
Triceps skinfold mm 14.9 6.26 13.4 5.44 12.6 5.87 12.7 4.77
Subscapular skinfold mm 21.2 7.38 19.0 6.37 16.8 6.01 16.6 4.93
Percent body fat % 28.6 6.04 27.1 5.89c 25.7 5.73 25.9 5.16
Arm muscle area cm2 48.3 12.4 45.2 ll.5c 40.2 9.64 39.7 8.59
Urine creatinine mg/day 16.98 316 1470 26l 1307 261 1185 244
Women
Number of subjects5 98—lOS 107—1 15 49—51 49—52
Protein intake from UUNg/kg/day 1.09 0.14 0.76 0.11 (1.73 t).09 0.47 Oll
Total protein intake from UUN 1.09 0.14 0.76 0.! l 0.73 0.09 0.65 0.11
g/kg/dayd
Energy intake kcal/kg/day 24.7 5.31 21.9 6.26 20.6 3.78 21.1 4.74
Albumin g/dl 4.02 0.25 4.02 0.26 4.03 0.35 4.01 0.34
Transferrin mg/dl 288 45.6 262 3935 253 34.9 252 42.9
Body weight kg 72.2 14.9 69.3 13.7 65.9 11.9 65.0 14.3
Relative body weight % 114 18.1 III 16.7 106 14.4 106 20.2
Biceps skinfold mm 13.1 6.15 11.8 6.42 9.43 5.58 9.88 5.65
Triceps skinfold mm 23.7 7.32 22.2 6.70 19.3 5.87 19.9 7.74
Subscapular skinfold mm 20.5 7.74 19.3 6.66 16.8 6.53 16.5 7.07
Percent body fat % 36.7 6.02 35.4 5.69 32.6 6.22 33.0 6.24
Arm muscle area cm2 30.7 13.7 28.9 11.9 29.8 10.9 27.0 14.3
Urine creatinine mg/day 1108 231 970 l73 912 153 789 l65
Data are given as mean standard deviation; Study A, GFR 25—55 ml/min/1.73 m2; Study B, GFR 13—24 ml/min/173 m2
Analyses are restricted to data obtained after the first four months of follow-up (F4); mean follow-up of patients included in the analysis was 2.5
years in Study A and 2.2 years in Study B
C Protein intake from food only (all diet groups)
d Total protein intake from food and amino acids in the ketoacid-amino acid supplement (very-low-protein diet group only)
P 0.05 between diet groups
'P 0.01 between diet groupsP  0.001 between diet group
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Fig. 1. Estimated mean changes in serum albumin concentrations (g/dl)
during follow-up. In this and subsequent figures, the values shown are
calculated as the mean of the differences between the data at the end of
baseline (the second or third visit, B2 or B3) and values during follow-up
visits (F) fur each individual patient. Data from men and women are
combined. Lines indicate the mean change from baseline at each time
point. Brackets indicate I standard error. Statistical tests compare mean
changes from baseline to the mean value during follow-up (beginning at
F4) in each diet group and between diet groups (see text). (A) In Study A,
serum albumin increased from baseline in the low-protein diet group (P <
0.001, dashed lines), but not in the usual-protein diet group (solid line).
However, the change in serum albumin was not significantly different
between the diet groups. (B) In Study B, serum albumin increased from
baseline in both the very-low-protein (dashed lines) and low-protein (solid
line) diet groups (P < 0.001), but the change was not significantly different
between diet groups.
Time, months
Fig. 2. Estimated mean changes in serum transferrin levels (mgldl)
during follow-up. (A) In Study A, serum transferrin declined from baseline
in the low-protein (solid line) diet group (P < 0.001), but not in the
usual-protein diet group (dashed lines). The change in serum transferrin
was greater (P < 0.001) in the low-protein diet group. (B) In Study B,
serum transferrin declined from baseline (P < 0.001) in both the
very-low-protein (dashed lines) and the low-protein diet groups (solid
line), but the change was not significantly different between diet groups.
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Safety measures. Patients in each study were grouped into
quartiles according to achieved protein intake, and the rates of
death, hospitalizations and stop points were compared among
quartiles (Table 5). Mean follow-up protein intake was not
associated with these outcomes in either Study A or Study B.
Changes in nutritional status variables from the fourth month to
the end of fbi/ow-up. As discussed earlier, some anthropometric
and biochemical indices of nutritional status changed gradually
during follow-up, while others showed abrupt changes within the
first four months and only gradual changes thereafter. To deter-
mine whether these gradual changes were associated with protein
intake, we related mean follow-up protein intake with changes in
these variables from the fourth month to the end of follow-up.
Table 6 shows the results of the univariate and multivariate
analyses. After controlling for a number of baseline factors and
for follow-up energy intake, the correlations and regression
coefficients (data not shown) were all weak and non-significant.
This indicates that changes in nutritional status variables from
four months to the end of follow-up were not associated with the
mean level of protein intake during follow-up. Additional analyses
(data not shown) revealed a significant univariate correlation
between the rates of decline in urine creatinine and GFR after the
fourth month of follow-up in Study B (r = 0.30, P < 0.001), but
not in Study A (r =
—0.002, P = 0.97).
DISCUSSION
Protein-calorie malnutrition is a well described important risk
factor for morbidity and mortality in maintenance hemodialysis
and peritoneal dialysis patients [25—28]. Many studies have dem-
onstrated a high prevalence of protein-calorie malnutrition in
dialysis patients [29—331. Moreover, the prevalence of protein-
calorie malnutrition in patients beginning dialysis treatment is
similar to that of patients who have undergone maintenance
dialysis for months or years [25, 30—321. This suggests that
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Fig. 4. Estimated mean changes in percent body fat (%) during follow.
Time, months up. (A) In Study A, the percent of body fat did not change significantly
from baseline in either diet group (dashed line, usual-protein; solid line,
Fig. 3. Estimated mean changes in body weight (kg) during follow-up, low-protein) and the change was not significantly different between diet
A) In Study A, weight declined from baseline in the low-protein diet groups. (B) In Study B, the percent of body fat declined from baseline in
group (solid line; P0.001), but not in the usual-protein diet group (dashed the low-protein group (solid line; P = 0.008) but not in the very-low-
line). The change in weight was greater (P 0.001) in the low-protein diet protein group (dashed lines). The decline was significantly greater in thegroup. (B) In Study B, weight declined from baseline in both the low-protein diet group (P = 0.02).
very-low-protein (dashed lines) and low-protein (solid line) diet groups,
but the change was not significantly different between diet groups.
remained within normal limits. The relative body wts averaged
above 100% (that is, the mean body wts remained above the
protein-calorie malnutrition in chronic renal disease often be- median weights of normal Americans of the same age, gender,
comes established before the onset of renal failure. Thus, it is height and frame size). Body fat and arm muscle area during the
essential that clinical recommendations for the use of low protein course of study also were not low [13]. Only two patients, both in
diets to slow the progression of chronic renal disease be accom- Study B, reached a stop point for malnutrition. In correlational
panied by demonstration of their safety. analyses, there was no apparent association between lower protein
The MDRD Study was the largest clinical trial thus far to intakes and higher rates of death, hospitalization, or other stop
examine the safety of dietary protein restriction, In Study A, points.prescribed and mean achieved protein intake were 1.3 and 1.11 On the other hand, there were changes over time and differ-glkg/day, respectively, in the usual-protein diet group, and 0.58
ences between the randomized groups in the mean values of many
and 0.77 glkglday, respectively, in the low-protein diet group [3].
nutritional indices (Figs. I to 6). This suggests that the nutritionalIn Study B, prescribed and mean achieved protein intake (from
status of some patients in the low-protein and very-low-proteinfood and supplement) were 0.58 and 0.73 g/kg/day, respectively, in
the low-protein diet group, and 0.56 and 0.66 g/kglday, respec- diet groups may have deteriorated, even though the mean values
tively, in the very-low-protein diet group [2]. Prescribed energy did not become abnormal during the course of the study. How-
intake was similar in all diet groups, requiring deliberate efforts to ever, with the exception of urine ereatinine, the mean change in
avoid weight loss concomitant with protein restriction. The results these variables was small, and the follow-up values remained
presented here indicate that nutritional status was in general well relatively stable at the lower levels. In Study A, there were
maintained in each diet group in both studies for periods of two to significant declines from baseline to follow-up in serum trans-
three years (Table 3). Serum albumin and transferrin values ferrin, body wt, arm muscle area and urine creatinine in the
Fig. 5. Estimated mean changes in arm muscle area (cm2) during follow
up. (A) In Study A, arm muscle area declined from baseline in the
low-protein diet group (P < 0.001; solid line) but not in the usual-protein
diet group (dashed line). The decline in arm muscle area was greater in
the low-protein group (P = 0.009). (B) In Study B, arm muscle area
declined from baseline in the very-low-protein diet group (P < 0.001), but
not in the low-protein diet group. Nonetheless, the decline was not
significantly different between the diet groups.
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Fig. 6. Estimated mean changes in urine creatinine excretion (mg/day)
during follow-up. Symbols in A are: (dashed lines) usual-protein; (solid
lines) low-protein. Symbols in B are: (dashed lines) low-protein; (solid
lines) very-low-protein. First, the mean value during follow-up (from F4)
was compared to the baseline (B3) value in each diet group (as for Figs.
1—5). (A) In Study A, urine creatinine excretion declined from baseline in
the low-protein diet group (P < 0.001) but not significantly in the
usual-protein diet group. The decline in urine creatinine excretion was
greater (P < 0.001) in the low-protein diet group. (B) In Study B, urine
creatinine excretion declined from baseline in both the very-low-protein
and the low-protein diet groups (P < 0.001). The decline was greater (P <
0.001) in the very-low-protein diet group. Second, the change from B3 to
F4 and from F4 to the end of follow-up was computed for each diet group
(two-slope method [11). In Study A, the decline in the low-protein diet
group was greated compared to the usual-protein diet group both before
(P < 0.001) and after (P = 0.013). In Study B, the decline in the
very-low-protein diet group as compared to the low-protein diet group was
faster before (P < 0.001) and slower after (P < 0.001) four months.
A
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low-protein diet group, but not in the usual-protein diet group.
Interestingly, there was a concomitant significant increase in mean
serum albumin concentration in the low-protein diet group but
not in the usual-protein diet group. In Study B, there were
significant declines from baseline to follow-up in serum trans-
ferrin, body wt, and urine ereatinine in both diet groups. During
the first four months, the decline in urine creatinine was signifi-
cantly greater in the very-low-protein diet group as compared to
the low-protein diet group, whereas after four months, urine
creatinine declined more slowly in the very-low-protein diet group
than in the low-protein diet group. In addition, there was a
significant decline in arm muscle area in the very-low protein diet
group and in percent body fat in the low-protein diet group.
Interestingly, there was also a concomitant significant increase
from baseline in serum albumin in both the very-low-protein and
low-protein diet groups.
For some indices, notably, mean serum transferrin, body wt and
urine creatinine, there was an abrupt decline within the first four
months after prescription of the low-protein and very-low-protein
diets, followed by a stabilization or more gradual decline there-
after. Thus, we reasoned that if dietary protein restriction had a
marked adverse effect on nutritional status, we would observe a
correlation between the rate of change in these parameters from
four months to the end of follow-up and the long-term average
value of achieved protein intake during the same interval. The
correlational analyses presented in Table 6 do not reveal signifi-
cant relationships with any of the variables examined. Overall, this
suggests that reductions in long-term protein intake over a wide
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Table 4. Rates of deaths, hospitalizations and stop points by study and diet groups
Study A Study B
Per patient—year Per patient—year
Diet group Event N of follow-up Diet group Event N
-
of follow-up
—
Usual-protein diet Deaths 9 1.3% Low-protein diet Deaths 1 0.3%(N = 294) First hosp. 66 11.1% (N = 129) First hosp. 32 12.7%
Stop points 46 6.7% Stop points 55 19.0%
Low-protein diet Deaths 2 0.3% Very-low-protein diet Deaths 4 1.4%
(N = 291) First Hosp. 63 10.3% (N = 126) First hosp. 28 11.6%
Stop points 38 5.5% Stop points 48 17.3%
a Study A, GFR 25—55 ml/min/1.73 m2; Study B, GFR 13—24 ml/min/173 m2
Table 5. Rates of deaths, first hospitalizations and stop points by study and quartiles of achieved protein intake
Study A Study B
Achieved Per patient-year Achieved Per patient-year
protein intakeb Event N of follow-up protein intak&'
-
Event N
-
of follow-up
<0.74 Deaths 1 0.3% <0.61 Deaths 0 0.0%
First hosp. 31 9.9% First hosp. 15 11.5%
Stop points 20 5.7% Stop points 26 17.5%
Total patients 145 Total patients 64
0.75—0.93 Deaths 1 0.3% 0.62—0.67 Deaths 1 0.7%
First hosp. 31 10.8% First hosp. 13 10.3%
Stop points 19 5.9% Stop points 22 14.9%
Total patients 144 Total patients 63
0.94—1.12 Deaths 5 1.5% 0.68—0.75 Deaths 1 0.7%
First hosp. 35 12.3% First hosp. 19 16.0%
Stop points 26 7.9% Stop points 23 16.0%
Total patients 144 Total patients 64
1.13 Deaths 3 0.9% 0.76 Deaths 3 2.4%
First hosp. 32 10.5% First hosp. 13 11.2%
Stop points 18 5.1% Stop points 31 24.5%
Total patients 145 Total patients 63
aStudy A, GFR 25—55 ml/min/1.73 m2; Study B, GFR 13—24 ml/min/173 m2
Protein intake for patients in the usual-protein and low-protein diet groups, total protein intake for patients in the very-low-protein diet group.
Protein intake and total protein intake are defined as the mean of all values beginning at the second month of follow-up (F2)
Table 6. Correlations between mean follow-up protein intake and rates of change in nutritional status variables during follow-up'
Study A Study B
Partial" Partialt
Nutritional status variable r P value r P value r P value r P value
Energy intake kcal/kg/day
Body weight kg
Percent body fat %
Albumin g/dl
Transferrin mg/dl
Urine creatinine mg/kg/day
—0.064
+0.073
+0.069
—0.061
+0.084
+0.079
0.14
0.09
0.12
0.15
0.05
0.07
—
+0.067
+0.005
—0.066
+0.075
+0.073
—
0.17
0.91
0.17
0.13
0.14
+0.022
+0.017
—0.010
+0.034
—0.095
—0.207
0.75
0.80
0.89
0.61
0.16
0.002
—
+0.045
+0.055
—0.016
—0.041
—0.140
—
0.55
0.47
0.83
0.59
0.06
a Protein intake for patients in the usual-protein and low-protein diet groups, total protein intake for patients in the very-low-protein diet group.
Protein intake and total protein intake are defined as the mean of all values beginning at the second month of follow-up (F2). Nutritional status variables
are computed for all values beginning at the fourth month of follow-up (F4).'Partial correlation, controlling for baseline (B3) measurement for age, gender, body weight, desire to lose weight, percent body fat, albumin,
transferrin, urine creatinine per kg body weight, total cholesterol and mean follow-up calorie intake. Analysis restricted to patients with  1 year of
follow-up. Interpretation: A positive sign indicates patients with higher protein intake had higher (less negative) slopes of rate of change in nutritional
status variables during follow-up.
range for two to three years were not associated with a progressive from synthesis of creatine in the liver or from ingestion of creatine
decline in nutritional status. in meat. A smaller proportion of urine creatinine is derived from
Nonetheless, the change in urine creatinine is striking and ingestion of creatinine in meat. Normally, steady-state urine
deserves further comment. Urine creatinine is derived largely creatinine excretion is nearly equal to creatinine generation, with
from the degradation of creatine in skeletal muscle originating little extra-renal elimination. In principle, the decrease in urine
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creatinine excretion that we observed may have several causes.
These include reduction in skeletal muscle mass [34, 35], reduc-
tion in creatine synthesis due to decreased protein intake [35, 36],
reduction in creatine degradation, decreased intake of meat
[35—371, and increased extra-renal elimination of creatinine, which
has been observed in chronic renal insufficiency due to degrada-
tion of creatinine by intestinal bacteria [38, 391. The reduction in
urine creatinine in the first four months after prescription of a
low-protein or very-low-protein diet (Fig. 6) is consistent with a
reduction in creatine and creatinine intake. However, this effect
would not be expected to lead to a continuing decline in creatinine
excretion over two to three years. The continued gradual fall in
urine creatinine throughout the follow-up period occurred in all
four diet groups and was not related to the level of achieved
protein intake. Possibly it indicates a reduction in muscle mass, as
suggested by the reduction in arm muscle area in some diet
groups. Alternatively, it could be due to a reduction in muscle
creatine degradation rate or an increase in extra-renal creatinine
elimination, neither of which were measured in this study.
Results from the MDRD Study [40], as well as from Ikizler et
al [41], show that the magnitude of urine creatinine excretion is
lower in patients with lower levels of renal function. Further, we
found that the rate of decline in creatinine excretion after four
months of follow-up correlated with the GFR decline in Study B.
This suggests that the gradual rate of decline in creatinine
excretion observed in both diet groups in Study B is related, in
part, to declining renal function. Nonetheless, the significantly
faster decline in the low-protein diet group (Fig. 6) suggests a
relationship to this diet, although not to the quantity of achieved
dietary protein intake. Interestingly, other studies of very-low-
protein diets supplemented with a mixture of essential amino
acids or ketoacids and amino acids also demonstrated reduced
creatinine excretion [42, 3I. Long-term follow-up of these studies
demonstrated no long-term adverse clinical effects of these diets,
including no increase in morbidity or mortality after beginning
maintenance dialysis [44, 45]. Additional studies will be necessary
to determine whether the faster decline in creatinine excretion in
patients following a low-protein or very-low-protein diet is an
indication of malnutrition.
The importance of the small changes in nutritional indices
other than urine creatinine is also not clear. A decrease in skinfold
thickness is considered to reflect a fall in body fat mass [33]. It is
noteworthy that the reductions in mean percent body fat that we
observed underestimate the actual decrease in body fat because
the mean body wt also decreased. A reduction in arm muscle area
is thought to reflect a loss of muscle protein or somatic protein
mass [33]. Decreases in serum albumin and transferrin are
considered to reflect a decrease in visceral protein mass [33],
which refers to proteins synthesized by the liver and other viscera.
The decrease in serum transferrin in the face of rising serum
albumin in the low-protein and very-low-protein diet groups is
somewhat puzzling. Serum transferrin has a shorter half-life,
about eight to nine days, in contrast to serum albumin which has
a half-life of about 18 to 20 days [46]. However, during the course
of a 2.2 years study, this small difference in half-lives should not be
influential. Serum albumin and transferrin are also influenced by
non-nutritional factors [46] that may have exerted different effects
on the serum concentrations. Serum albumin was measured by a
dye binding method that may overestimate albumin levels in
individuals with chronic renal failure [46]. However, the decrease
in GFR during the study did not seem to be of sufficient
magnitude to account for a change in the dye binding to albumin.
Possibly, the decrease in serum transferrin may reflect a specific
response to declining renal function.
The causes for protein-calorie malnutrition in patients with
renal failure have been reviewed elsewhere [29, 47]. A major
cause of malnutrition is considered to be reduced nutrient intake.
Hence, it is pertinent that the groups of patients that displayed the
greatest mean decline in nutritional parameters were the low- and
very-low protein diet groups. On the other hand, low-protein diets
and very-low-protein diets have been shown in previous metabolic
balance studies to maintain nitrogen balance [48—52].
Possibly the conclusions of these metabolic balance studies are
not applicable to patients with chronic renal disease in the
MDRD Study for the following reasons. First, short-term studies
of 15 to 40 days duration may not indicate the quantities of dietary
protein necessary to maintain long-term protein balance. Second,
the patients who underwent nitrogen balance studies with these
low- or very-low-protein diets had more advanced renal disease
than most of the participants in the MDRD Study. Possibly,
patients with more advanced renal disease might tolerate these
diets better, because they may already have experienced some
degree of protein wasting. Third, the dietary energy intake in the
balance studies was higher than the mean achieved energy intake
in the MDRD Study, especially in the low-protein and very-low-
protein diet groups. Fourth, the range of achieved protein intake
observed in the MDRD Study included some patients with lower
protein intakes than in the balance studies.
However, it is likely that protein intake was sufficient in most
patients for the following reasons. The mean achieved protein
intakes (from food and supplement) in the low-protein and
very-low-protein diet groups during follow-up (from 0.66 to 0.77
g/kg/day [2, 31) were well above the level (about 0.6 g/kg/day) that
has been shown to maintain nitrogen balance in previous meta-
bolic balance studies [48—52]. Moreover, the mean achieved
intakes in these diet groups were not much lower than the
Recommended Dietary Allowances of the Food and Nutrition
Board [531. This allowance, about 0.80 g of miscellaneous biolog-
ical value protein/kg/day for nonpregnant, nonlactating normal
adults, is believed to provide a surfeit of protein for most normal
men and women [531. Finally, the correlational analyses that we
performed, controlling for baseline nutritional status and fol-
low-up energy intake, do not reveal a relationship between lower
protein intake and long-term deterioration in nutritional status
across a broad range of intakes.
The metabolic and endocrine disorders associated with renal
failure per se may have contributed to the decline in nutritional
indices. The baseline GFR of most patients in the MDRD Study
was above the level that would traditionally be considered to cause
severe metabolic abnormalities (Table 1). However, the rate of
GFR decline was variable and some patients in both Studies A
and B developed renal failure. Moreover, we have reported
preliminary data suggesting that alterations in dietary intake and
indices of nutritional status are observed beginning at GFR values
from 30 to 50 ml/min/1.73 m2 [54]. Thus, declining renal function
seems likely to be responsible, at least in part, for some of the
observed changes in nutritional status.
Another possible cause for the decline in nutritional indices in
these patients is low energy intake. Mean energy intake was below
normal at baseline and declined further in all four diet groups
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(Tables 2 and 3), due in part to the desire of many study
participants (about 65% in Study A and 50% in Study B) to lose
weight. However, weight loss was most pronounced in the low-
protein and very-low-protein diet groups. In these latter groups,
the mean energy intake fell by 3.1 to 4.3 kcal!kg/day to mean
values ranging from 20.7 to 23.3 kcal/kglday during follow-up
(Table 3). In contrast, in the usual-protein diet group, mean
energy intakes in men and women during follow-up averaged 26.7
and 24.8 kcallkglday, respectively (Table 3). For comparison, the
Recommended Dietary Allowances by the Food and Nutrition
Board for energy intake in normal men and women undergoing
light physical activity is approximately 35 kcal/kglday for adults 60
years old or younger and 30 kcallkg!day for individuals 61 years of
age or older [53]. Studies of nondialyzed patients with chronic
renal failure suggest that their energy expenditure and energy
requirements are not different from normal [51, 55]. Thus, the low
dietary energy intakes of the patients in the MDRD Study at
baseline and during follow-up can be considered to be maladap-.
tive and probably inadequate for their nutritional needs. The
nutritional hazards of low energy intake may be enhanced in
individuals ingesting low protein diets, because the ability to
maintain nitrogen balance may be strongly dependent on the
magnitude of dietary energy intake [51].
The finding that energy intake was lower with the low-protein
and very-low-protein diet groups, as compared to the usual-
protein diet group, suggests that the quantity of dietary protein or
phosphorus prescribed may have influenced the patients' energy
intakes. Indeed, the patients assigned to these latter two diets
described more difficulty in attaining the prescribed energy intake
than did the patients assigned to the usual protein diet. This
probably reflects the reduced food choices available with these
latter diets. In fact, many of the MDRD Study dietitians indicated
that they had more difficulty in providing the prescribed energy
intake with their meal plans for patients in the low-protein and
very-low-protein diet groups, as compared to the usual-protein
diet group. These findings underscore the necessity for intensive
dietary counseling and monitoring of nutritional status during
initiation and follow-up of dietary protein restriction.
In summary, nutritional status was generally well-maintained
over the two to three years follow-up in the MDRD Study. We
found no definite evidence of malnutrition in patients in any of the
diet groups. Neither the comparisons of randomized groups nor
correlational analyses showed an association of higher rate of
death, hospitalization, or the frequency of predetermined stop
points with lower protein intake. On average, most anthropomet-
tic and biochemical indices of nutritional status remained within
the normal range. However, there were some changes from
baseline to follow-up in a variety of nutritional variables and
differences in these changes between the randomized groups. In
the low-protein and very-low-protein diet groups, mean serum
albumin remained constant or rose slightly during follow-up.
Mean serum transferrin, weight, percent body fat, and arm muscle
area declined, but the decrease was mild and not progressive.
Mean urine creatinine excretion declined soon after prescription
of the low-protein and very-low-protein diets, probably due to
reduced meat intake. In addition, urine creatinine continued to
decline thereafter in all diet groups. The achieved level of protein
intake was not related to the rate of decline in any of these
nutritional variables.
Secondary analyses from the MDRD Study [2, 3] and two
meta-analyses of randomized trials [4,5] provide some support for
the hypothesis that protein and phosphorous restriction slows the
progression of renal disease. Overall, the analyses presented here
show that the dietary intervention program used in the MDRD
Study is safe for a period of two to three years. However, the small
but significant decline in various indices of nutritional status is of
concern because of the simultaneous reduction in protein and
energy intake in the low-protein and very-low-protein diet groups,
and because of the high incidence and adverse effect of protein-
calorie malnutrition in patients with end-stage renal disease. We
suggest that physicians who prescribe low-protein diets must
carefully and frequently monitor patients' protein and energy
intake and nutritional status. The involvement of a skilled dieti-
tian is essential to assist patients in simultaneously adhering to the
protein restriction and maintaining sufficient energy intake.
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APPENDIX
Dietary intervention
Research dietians trained the patients to prepare and follow their
prescribed diets, monitored patients' nutrient intakes and provided dietary
counseling and performed anthropometric measurements. Dietitians were
trained by the MDRD Study Nutritional Coordinating Center in the
education, monitoring and counseling of patients with regard to their
dietary intake and in anthropometry. Each dietitian was required to he
certified and that he or she had obtained a standard of accuracy and
reproducibility in the asessment of the patients' nutrient intake and the
performance of anthropometry before he or she was allowed to train
patients or collect data for the study. The methods employed by the
Nutrition Coordinating Center for these procedures are described else-
where [14-17].
The protein and phosphorus content of the three prescribed diets was as
follows: usual-protein diet, 1.30 g protein per kg body wt per day (target
range 0.975 to 1.625) and 16 to 20 mg phosphorus per kg per day;
low-protein diet, 0.575 g protein per kg per day (target range 0.402 to
0.748) and 5 to 10 mg phosphorus per kg per day; very-low-protein diet,
0.28 g protein per kg per day (target range 0.224 to 0.420), 0.28 g/kg/day
of a ketoacid-amino acid mixture (Ross Laboratories, Columbus, OH,
USA) and 4 to 9mg phosphorus per kg per day. The biological value of the
other two protein diets was not specified. All dietary prescriptions and
estimates of dietary intake are expressed according to the patients'
standard body weight. Standard body weight refers to the median value for
weights of normal Americans of the same age, range, height, gender and
skeletal frame size as the patient, as determined from the NHANES I and
II data [13]. The composition of the ketoacid-amino acid mixture (jLmol/
kg/day) was as follows: (L)-tyrosine 271, (L)-threonine 119, calcium 17,
(D,L)-hydroxymethylthiohutyrate 34, (L)-tryptophan 4, and a mixture of
basic amino acid salts containing the following components, (L)-ornithine
491, (L)-lysine 237, (L) histidine 68, ketoisocaproate 305, ketoisovalerate
254, and (R,S) ketomethylvalerate 237. In each diet group dietary protein
was increased by I gram of high biological value protein for each gram of
urinary protein excreted per day up to a total of 8 g per day of protein.
The dietary prescriptions did not differ for nutrients other than protein,
phosphorus and the ketoacid supplement. Patients were prescribed at
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least 30 kcal/kg standard body weight/day unless they were overweight
(greater than 115% of standard body weight), gaining unwanted weight or
fearful of gaining weight. Patients who were underweight or losing weight
were often prescribed higher calories. Patients who were overweight,
particularly those with hypertension, hyperlipidemia or non-insulin-de-
pendent diabetes mellitus, were prescribed a weight reduction diet with an
energy intake between 25 and 30 kcal/kg/day.
The daily intake of other nutrients were as follows: calcium 1300 to 1700
mg (including supplements of calcium carbonate tablets), magnesium 300
to 350 mg, sodium 1200 mg or greater, potassium 50 to 150 mg, iron 10 mg
or greater for men and 18 mg or greater for women, zinc 15 to 20 mg/day
(including zinc supplements, see below) and vitamin A about 5,000 IU.
Patients were prescribed one multivitamin/mineral tablet each day that
provided the following nutrients per day: thiamine 1.5 mg, riboflavin 1.7
mg, niacinamide 20 mg, pyridoxine hydrochloride 10 mg (8.12 mg of free
pyridoxine), panthothenie acid 10 mg, vitamin B12 6 g, biotin 300 jzg,
ascorbic acid 60 mg, folic acid I mg, cholecalciferol 5 g, vitamin E 6 mg,
and zinc 8 mg.
Measurements
Dietary protein intake was estimated at monthly intervals from the
urine urea excretion according to the following formula [17]. Protein
intake (g/day) = 6.25 [UUN (g/day) + 0.31 (g/kg/day) x SBW (kg)], where
UUN is urea nitrogen and SBW is standard body weight. In Study B, this
value included protein intake from food as well as amino acids in the
ketoacid-amino acid supplement, and for convenience is termed "total
protein intake" [2]. Dietary nutrient intake was also calculated at three-
month intervals from dietary diaries and interviews. Each clinical center
dietitian calculated the patient's nutrient intake using the University of
Pittsburgh Nutrient Database [141. Compliance to intake of the ketoacid-
amino acid mixture was estimated by pill count and by measuring plasma
alloisoleucine concentrations.
Weight (wearing street clothes without shoes) was obtained monthly.
Height, measured with a wall-mounted stadiometer, and skeletal frame
size, assessed by measuring the hiocondylar width of the elbow of the
dominant arm using a Biocondylar Vernier calipers, were assessed at the
second month of baseline (B2) and then annually. Mid arm circumference
(MAC) and skinfold thickness in the triceps, biceps and subscapular areas
were measured at B2 and six month intervals thereafter. A metal tape was
used for measuring MAC, and a Holtain calipers (Holtain Ltd., Crymych,
UK) was used for measuring skinfold thickness. The percent relative body
weight was calculated as the patient's weight x 100/SBW. The percent of
body fat was estimated from body weight and height and the biceps, triceps
and subscapular skinfold thicknesses using the equations of Durnin and
Wormersley [18]. Arm muscle area (AMA) was calculated at the mid arm
from the MAC and the triceps skinfold thickness according to the
following equation [19]: AMA (cm2) = [MAC — r X triceps skinfold
thickness (cm)]2/4. AMA measurements presented in this paper were
corrected to delete bone mass using the following equations: AMA (men)
= AMA — 1900; AMA (women) = AMA — 1550.
Serum albumin and transferrin were measured at monthly intervals.
Albumin concrentrations were determined by dye-binding using brom-
cresol green reagents and an Astra 8 analyzer obtained from Beckman
Instruments (Brea, CA, USA). Transferrin concentrations were deter-
mined by immununcphrolometry using reagents including specific anti-
body and calibrators, and an Array nephelometer obtained from Beckman
Instruments. Urine was collected over a 24 hour period for measurement
of urea, creatinine and protein at monthly intervals. GFR was measured
by the renal clearance of '251-iothalamate as previously described [21, 22].
These measurements were performed in the MDRD Study Central
Biochemistry Laboratory and GFR Laboratory at the Cleveland Clinic
Foundation. Normal values for some of the nutritional parameters are as
follows: serum albumin 4.0 to 5.0 g/dl, serum transferin 250 to 300 mg/dl
and relative body weight 90% to 110%.
Action items and stop points
An action item was defined as the occurrence of a condition requiring
modification of diet, vitamin prescription or frequency of measurement.
Action items were defined in the protocol and reported as they occurred.
Action items specifically related to serum protein levels or weight and the
responses to these action items included the following: (1) Weight loss,
defined as an undesired weight loss of greater than 2.5 kg below the
patient's weight at the end of the second month of the baseline period
(B2) or of 5% of standard body weight, whichever was less, or a loss of
weight to less than 80% of standard weight. The response was to increase
the dietary energy intake. (2) Weight gain, defined as a gain in weight
greater than 5% of the patient's B2 weight (in the absence of edema). (3)
Overweight diabetic, defined as weight greater than 115% of standard
weight in a diabetic patient (in the absence of edema). For the latter two
action items, the response was to reduce the energy intake. (4) Declining
serum albumin, defined by a decrease in serum albumin by more than 0.5
g/dl from the B3 value to a value between 3.0 and 3.9 g/dl. (5) Low serum
albumin, defined as a decrease serum albumin to below 3.0 g/dl. For the
latter two action items, the response was to first increase the energy
prescription; if this was unsuccessful in raising serum albumin, then the
dietary protein intake was increased. For patients in any diet group whose
protein intake was below the target range, the patient was urged to raise
protein intake to target levels for patients whose dietary protein intake was
above the target range, there was no recommended change in protein
intake in response to the declining serum albumin. For patients whose
dietary protein intake was at the target range, the response was to increase
protein intake to 0.70 g/kg/day for patients prescribed the low-protein diet
(50% of the increase in protein was of high biological value protein) and
to 0.40 g/kg/day for patients prescribed the very-low-protein diet for
patient prescribed the usual-protein diet whose dietary protein intake was
within the target range, no increase in protein intake was recommended
for a decreasing serum albumin. (6) Declining serum transferrin was
defined as a decrease by more than 50 mgldl below the B3 level to a value
below 200 mg/dl. The response was the same as for a declining serum
albumin level.
In addition, there were numerous other action items requiring specific
dietary modifications, including alterations in serum concentrations of
phosphorus, calcium, potassium, bicarbonate, magnesium, iron, total
cholesterol, LDL cholesterol, and triglycerides. As reported elsewhere,
there were other action items related to compliance with the prescribed
dietary protein or ketoacid-amino acid supplements [111 or the blood
pressure intervention [101.
A stop point was a defined adverse event after which the investigator
was no longer obligated to treat the patient with his study diet or blood
pressure goal. Stop points specifically related to nutritional status included
the following: (1) low serum albumin, defined as persistent serum albumin
less than 3.0 gldl for more than four consecutive months. (2) Weight loss,
defined as persistent body weight less than 75% of standard for three
months after dietary intervention for a weight loss action item. (3) Very
high serum phosphorus, defined as fasting serum phosphorus greater than
6.0 mg/dl on four consecutive monthly measurements after a high serum
phosphorus action item. In addition, there were other stop points for onset
of renal failure, rapid decline in GFR (Study A only), and serious
intercurrent medical conditions.
Information on hospitalization was obtained routinely during study
visits or if a study visit was missed. Patient deaths were reported using a
special form. Information about cause of death was sought from several
sources, induding family members, hospital records, and a copy of the
death certificate. Cause of death was classified by the clinical center
principal investigators.
In addition to these activities, a subcommittee of the External Moni-
toring Committee met at regular intervals during the follow-up period to
review detailed statistical summaries of these events. Profiles of dietary
and nutritional status variables were also prepared for individual patients
selected because of either undesired weight loss or changes in biochemical
or anthropometric indices of nutritional status that were not sufficient to
trigger a stop point. The subcommittee found no serious problems related
to the safety of either diet intervention in either study.
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